RT Journal Article SR Electronic T1 Streptococcus pneumoniae colonisation associates with impaired adaptive immune responses against SARS-CoV-2 JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2021.07.22.21260837 DO 10.1101/2021.07.22.21260837 A1 Mitsi, Elena A1 Reiné, Jesús A1 Urban, Britta C A1 Solórzano, Carla A1 Nikolaou, Elissavet A1 Hyder-Wright, Angela D. A1 Pojar, Sherin A1 Howard, Ashleigh A1 Hitchins, Lisa A1 Glynn, Sharon A1 Farrar, Madlen A1 Liatsikos, Konstantinos A1 Collins, Andrea M A1 Walker, Naomi F A1 Hill, Helen A1 German, Esther L A1 Cheliotis, Katerina S A1 Byrne, Rachel L A1 Williams, Christopher T. A1 Cubas-Atienzar, Ana I A1 Flecher, Tom A1 Adams, Emily R A1 Draper, Simon J A1 Pulido, David A1 Beavon, Rohini A1 Theilacker, Christian A1 Begier, Elizabeth A1 Jodar, Luis A1 Gessner, Bradford D A1 Ferreira, Daniela M YR 2021 UL http://medrxiv.org/content/early/2021/07/28/2021.07.22.21260837.abstract AB Although recent epidemiological data suggest that pneumococci may contribute to the risk of SARS-CoV-2 disease, secondary pneumococcal pneumonia has been reported as infrequent. This apparent contradiction may be explained by interactions of SARS-CoV-2 and pneumococcus in the upper airway, resulting in the escape of SARS-CoV-2 from protective host immune responses. Here, we investigated the relationship of these two respiratory pathogens in two distinct cohorts of a) healthcare workers with asymptomatic or mildly symptomatic SARS-CoV-2 infection identified by systematic screening and b) patients with moderate to severe disease who presented to hospital. We assessed the effect of co-infection on host antibody, cellular and inflammatory responses to the virus. In both cohorts, pneumococcal colonisation was associated with diminished anti-viral immune responses, which affected primarily mucosal IgA levels among individuals with mild or asymptomatic infection and cellular memory responses in infected patients. Our findings suggest that S. pneumoniae modulates host immunity to SARS-CoV-2 and raises the question if pneumococcal carriage also enables immune escape of other respiratory viruses through a similar mechanism and facilitates reinfection occurrence.Competing Interest StatementRB, CT, EB, LJ and BDG are employees of Pfizer, and may own Pfizer stock.Funding StatementThe study was supported by funding from the National Institute for Health Research Health Protection Research Unit (NIHR HPRU) in Emerging and Zoonotic Infections, the Centre of Excellence in Infectious Diseases Research (CEIDR) and the Alder Hey Charity via the Liverpool COVID-19 Partnership Strategic Research Fund to N.F.W and Pfizer grant no. WI255862-1 awarded to E.M and D.M.F.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:NHS Health Service Research Ethics Committees (ref 20/SC/0147 and 20/SC/0169)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesLSTM repository